Cargando…
Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer
INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194982/ https://www.ncbi.nlm.nih.gov/pubmed/35734053 http://dx.doi.org/10.1002/lio2.790 |
_version_ | 1784726865261363200 |
---|---|
author | Supanimitjaroenporn, Pasawat Kirtsreesakul, Virat Tangthongkum, Manupol Leelasawatsuk, Peesit Prapaisit, Usaporn |
author_facet | Supanimitjaroenporn, Pasawat Kirtsreesakul, Virat Tangthongkum, Manupol Leelasawatsuk, Peesit Prapaisit, Usaporn |
author_sort | Supanimitjaroenporn, Pasawat |
collection | PubMed |
description | INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from 211 advanced‐stage oral cancer patients treated with curative intent between January 2009 and December 2015 were obtained from the hospital information system. Pretreatment LMR and other hematologic parameters were recorded and an LMR cutoff value was calculated. Overall survival between the groups above (high LMR) and below (low LMR) the cutoff was compared and hazard ratios from univariate and multivariate analyses using a Cox proportional hazards model calculated. RESULTS: Overall survival and disease‐specific survival were better in the high LMR group. The 5‐year overall survival rates were 31.6% and 15% in the high LMR and low LMR groups, respectively. Multivariate analysis using a Cox proportional hazards model showed that treatment modality and LMR were the only factors associated with overall survival. CONCLUSION: Low LMR was associated with poor survival outcome in patients with advanced‐stage oral cavity cancer. LEVEL OF EVIDENCE: 2b. |
format | Online Article Text |
id | pubmed-9194982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91949822022-06-21 Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer Supanimitjaroenporn, Pasawat Kirtsreesakul, Virat Tangthongkum, Manupol Leelasawatsuk, Peesit Prapaisit, Usaporn Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology INTRODUCTION: Lymphocyte‐to‐monocyte ratio (LMR) has been reported as a prognostic factor in many cancers but the data are to date limited for its use in oral cavity cancer. The purpose of this study was to evaluate the prognostic value of LMR in advanced‐stage oral cavity cancer. METHODS: Data from 211 advanced‐stage oral cancer patients treated with curative intent between January 2009 and December 2015 were obtained from the hospital information system. Pretreatment LMR and other hematologic parameters were recorded and an LMR cutoff value was calculated. Overall survival between the groups above (high LMR) and below (low LMR) the cutoff was compared and hazard ratios from univariate and multivariate analyses using a Cox proportional hazards model calculated. RESULTS: Overall survival and disease‐specific survival were better in the high LMR group. The 5‐year overall survival rates were 31.6% and 15% in the high LMR and low LMR groups, respectively. Multivariate analysis using a Cox proportional hazards model showed that treatment modality and LMR were the only factors associated with overall survival. CONCLUSION: Low LMR was associated with poor survival outcome in patients with advanced‐stage oral cavity cancer. LEVEL OF EVIDENCE: 2b. John Wiley & Sons, Inc. 2022-03-30 /pmc/articles/PMC9194982/ /pubmed/35734053 http://dx.doi.org/10.1002/lio2.790 Text en © 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Head and Neck, and Tumor Biology Supanimitjaroenporn, Pasawat Kirtsreesakul, Virat Tangthongkum, Manupol Leelasawatsuk, Peesit Prapaisit, Usaporn Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title | Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title_full | Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title_fullStr | Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title_full_unstemmed | Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title_short | Prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
title_sort | prognostic value of pretreatment lymphocyte‐to‐monocyte ratio in patients with advanced oral cavity cancer |
topic | Head and Neck, and Tumor Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194982/ https://www.ncbi.nlm.nih.gov/pubmed/35734053 http://dx.doi.org/10.1002/lio2.790 |
work_keys_str_mv | AT supanimitjaroenpornpasawat prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer AT kirtsreesakulvirat prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer AT tangthongkummanupol prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer AT leelasawatsukpeesit prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer AT prapaisitusaporn prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithadvancedoralcavitycancer |